Approval · Notice of Compliance 385 · 2002
REACTINE: Notice of Compliance 385
Issued March 11, 2002
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 385
- Date
- March 11, 2002
- Company
- Pfizer Canada Inc., Consumer Healthcare DivisionMarkham, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Manufacturer name change
- Therapeutic class
- Histamine h1 receptor antagonist
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| REACTINE | 01900978 | Marketed |
Medicinal ingredients
- CETIRIZINE HYDROCHLORIDE 20 MG per TAB